🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsTirzepatide (Mounjaro / Zepbound)Compounded tirz stability at room temperature — 14-day data

Compounded tirz stability at room temperature — 14-day data

kate.chem Mon, Apr 20, 2026 at 9:09 AM 26 replies 804 viewsPage 1 of 6
kate.chem
VIP Member
3,890
17,654
Dec 2023
California
Apr 20, 2026 at 9:09 AM#1

Posting this because the summary going around does not say what the paper says, and the difference matters for how people here are using it.

Freezing is the one to avoid, and freeze-thaw more so. Ice-crystal formation and the concentration changes at the phase boundary drive aggregation, and aggregated peptide does not recover on thawing. A vial that has been frozen and thawed is not rescued by returning it to the fridge.

Where I think it is weakest: the follow-up is short relative to how long people actually take these drugs, so durability is an assumption here rather than a finding.

What would genuinely help is knowing what a temperature excursion actually does, and what distinguishes an unopened vial from one already in use. Numbers rather than impressions, if you have them.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
34 4steve_okc, dave_SLC, FDA_TrackerJim and 31 others
Reply Quote Save Share Report
Dr.MetabolicMD
VIP Member
2,345
16,789
Jan 2024
Rochester, MN
Apr 20, 2026 at 11:23 AM#2
kate.chem said:
Freezing is the one to avoid, and freeze-thaw more so.

No disagreement with kate.chem. One condition attached. Worth adding the genuine exception, because it is real and narrow: a change made for an identified patient where the prescriber determines it produces a significant clinical difference for that patient. A grid of fixed doses offered to everybody is not that, whatever the intake form says.

33 3PedsEndoPhilly, SleepDoc_PDX, RegAffairsDC and 30 others
Reply Quote Save Share Report
Dr.PainCLE
Senior Member
1,234
6,234
Mar 2024
Cleveland, OH
Apr 20, 2026 at 1:37 PM#3
kate.chem said:
Freezing is the one to avoid, and freeze-thaw more so.

I read this differently from kate.chem, on substance rather than tone. The distinction that matters is unopened versus in use. Unopened vials are stable refrigerated for their labelled shelf life and tolerate a limited excursion to room temperature. Once reconstituted, the clock is much shorter and is set by the preservative rather than by the peptide — bacteriostatic water's benzyl alcohol is what buys you multiple draws over weeks. Sterile water has no preservative and turns a multi-dose vial into a single-use one.

32 2oliver_london, tane_welly, Dr.PathRoch and 29 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
newstart_MO
New Member
12
45
Feb 2026
Springfield, MO
Apr 20, 2026 at 3:51 PM#4

Short answer first, then the reasoning. They are two different exemptions from the same federal requirements and they buy different things. A 503A pharmacy is regulated primarily by the state board, needs a patient-specific prescription, is exempt from CGMP, and may use a bulk substance that has a USP monograph, is a component of an approved drug, or appears on the 503A bulks list — three independent doorways. A 503B outsourcing facility registers with the FDA, is inspected on a risk basis, must comply with CGMP, may compound for office stock without a patient-specific prescription, and has one doorway to a permitted bulk substance: the 503B bulks list, or the drug shortage list.

Last edited: Apr 20, 2026 at 9:51 PM
31 1TrialNerd_Beth, HPLC_Greg, LibrarianMeg and 28 others
Reply Quote Save Share Report
tane_welly
Member
234
1,123
Sep 2024
Wellington, NZ
Apr 21, 2026 at 5:08 AM#5
Dr.MetabolicMD said:
Worth adding the genuine exception, because it is real and narrow: a change made for an identified patient where the prescriber determines it produces…

Can confirm. Same sequence, different timescale. The detail I would add is minor and it is already implied above.

30 0pam_columbus, nick_SD_fit, ben_calgary and 27 others
Reply Quote Save Share Report
1236

Similar Threads

SURMOUNT-5: Tirzepatide vs semaglutide head-to-head — full results11 replies
SURPASS 1-5 program: tirzepatide T2DM efficacy data compilation6 replies
Tirzepatide dual agonism: GIP + GLP-1 synergistic mechanism18 replies
5mg → 10mg → 15mg titration — clinical guidance and real-world data8 replies
Zepbound insurance coverage — payer-by-payer breakdown 20268 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register